Abstracts tagged "TNF-blocking Antibody"

Abstract Number: 0129 • ACR Convergence 2022
Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Marinella Govoni¹, Anastas Batalov², Dimitrios Boumpas³, Salvatore D'Angelo⁴, Filip De Keyser⁵, Rene-Marc Flipo⁶, Herbert Kellner⁷, Hermine Leroi⁸ and Ahmed Khalifa⁹, ¹MSD Italy, Cento, Italy, ²Medical University of Plovdiv, Plovdiv, Bulgaria, ³National and Kapodistrian University of Athens, Heraklion, Greece, ⁴Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ⁵Department of Rheumatology, Ghent University Hospital, Maldegem, Belgium, ⁶CHU Lille, Boulogne-Billancourt, France, ⁷Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁸MSD Belgium, Woluwe-Saint-Lambert, Belgium, ⁹MSD Sharp & Dohme GmbH, Germany, Kriens, Switzerland
Background/Purpose: Patients with inflammatory arthritis often experience secondary non-response to a first-line tumor necrosis factor alpha inhibitor (TNFαi). GO-BEYOND is a study program comprised of…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…
Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Steven Feldman¹, Heimo stroissnig², Richard Kay³, Joanna Sobierska⁴, Roshan Dias⁴, Eric Guenzi⁵, Hendrik Otto², Halimuniyazi Haliduola², Abid Sattar⁶, Ruth Ruffieux⁴, Matjaz Steijger⁴ and Fausto Berti⁴, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²Alvotech, Jülich, Germany, ³RK Statistics, Bakewell, United Kingdom, ⁴Alvotech, Zürich, Switzerland, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, London, United Kingdom
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Katherine Liao¹, Jon Giles², Pamela Rist¹, Robert Glynn¹, Leah Santacroce¹, Paul Ridker¹, Ahmed Tawakol³, Joan Bathon² and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…
Abstract Number: 1505 • ACR Convergence 2022
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
Nina Colla¹, Julia-Tatjana Maul², Burkhard Moeller³, Michael Nissen⁴, Nikhil Yawalkar⁵, Eleftherios Papagiannoulis⁶, Oliver Distler¹, Adrian Ciurea⁷ and Raphael Micheroli⁸, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Dermatology and Venereology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Inselspital - University Hospital Bern, Bern, Switzerland, ⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁵Department of Dermatology, University Hospital Inselspital Bern, Bern, Switzerland, ⁶Statistics Group, SCQM Foundation, Zurich, Switzerland., Zürich, ⁷University Hospital Zurich, Zürich, Switzerland, ⁸University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland
Background/Purpose: Biomechanical stress is a possible trigger of inflammation in psoriatic arthritis (PsA). The influence of physically demanding occupations on this potential association has not…
Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
SE RIM CHOI¹, Anna Shin², You-Jung Ha², Yun Jong Lee², Eun Bong Lee¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
Abstract Number: 1510 • ACR Convergence 2022
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
Gareth Jones¹, Ovidiu Rotariu¹, Brigitte Michelsen², Bente Glintborg³, Bjorn Gudbjornsson⁴, Arni Geirsson⁵, Heikki Relas⁶, Pia Isomäki⁷, Jakub Závada⁸, Karel Pavelka⁹, Ziga Rotar¹⁰, Matija Tomsic¹⁰, Michael Nissen¹¹, Adrian Ciurea¹², Catalin Codreanu¹³, Johan Karlsson Wallman¹⁴, Eirik Kristianslund¹⁵, Simon Rasmussen¹⁶, Lykke Ørnbjerg¹⁷, Maria José Santos¹⁸, Mikkel Østergaard¹⁹, Merete L Hetland²⁰ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, Scotland, United Kingdom, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Kristiansand, Norway, ³Rigshospitalet, Glostrup, Virum, Denmark, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁶Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ⁷Centre for Rheumatology, Tampere University Hospital, Tampere, Finland, ⁸Institute of Rheumatology, Prague, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹Hopitaux Universitaires de Genève, Geneva, Switzerland, ¹²University Hospital Zurich, Zürich, Switzerland, ¹³Center for Rheumatic Diseases, Bucharest, Romania, ¹⁴Lund University and Skane University Hospital, Hjarup, Sweden, ¹⁵Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ¹⁷Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹⁸Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ¹⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ²⁰Rigshospitalet, Glostrup, Denmark
Background/Purpose: In axial spondyloarthritis (axSpA) much attention has been focused on pharmacological management, including tumour necrosis factor inhibitors (TNFi), as a means to reducing inflammation,…
Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk¹, Nevin Hammam², Jing Li³, David Collier⁴, Greg Kricorian⁵ and Scott Stryker⁶, ¹UCSF / SFVA, San Francisco, CA, ²Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen Inc., San Francisco, CA
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
Abstract Number: 1553 • ACR Convergence 2022
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Faustino Peron Filho¹, Andressa de Souza Moreira², Anna Larissa Janes² and Alexandre Wagner de Souza², ¹UNIFESP-EPM, Mogi das Cruzes, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil
Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…
Abstract Number: 0577 • ACR Convergence 2021
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Diviya Rajesh, Deanna Jannat-Khah, Huong Do, Jonah Levine, Medha Barbhaiya, Lisa Mandl and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Higher comorbidity burden (CB) has been associated with treatment choices in RA, but not assessed in populations including multiple forms of inflammatory arthritis (IA)…
Abstract Number: 1251 • ACR Convergence 2021
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Borja Hernandez-Breijo¹, Ioannis Parodis², Chamaida Plasencia-Rodríguez³, Mariana Díaz-Almirón⁴, Ana Martínez-Feito⁵, Marta Novella-Navarro³, Dora Pascual-Salcedo¹ and Alejandro Balsa³, ¹Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ³Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: The latest breakthroughs in the pathophysiology of rheumatoid arthritis (RA) highlighted the activation of B cells as a trigger of the joint flare initiation…
Abstract Number: 1223 • ACR Convergence 2020
Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History
Piyam Das¹, Sicong Huang², Kumar Dahal², Huahua Zheng³, Jonathan Coblyn², Michael Weinblatt², Tianxi Cai¹ and Katherine Liao², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA
Background/Purpose: IIn rheumatoid arthritis (RA), a patient’s biologic disease modifying anti-rheumatic drug (bDMARD) history and the duration of time they remain on each drug may…
Abstract Number: 1227 • ACR Convergence 2020
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors
Borja Hernandez-Breijo¹, Chamaida Plasencia², Victoria Navarro-Compán³, Israel Nieto-Gañán⁴, Cristina Sobrino⁵, Ana Martínez-Feito⁶, Carlota García-Hoz⁴, Paloma Lapuente-Suanzes⁴, Javier Bachiller-Corral⁷, Gema Bonilla², Cristina Pijoán-Moratalla⁷, Garbiñe Roy⁴, Mónica Vázquez⁷, Alejandro Balsa², Luisa M Villar⁴, Dora Pascual-Salcedo⁸ and Eulalia Rodríguez-Martín⁴, ¹Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ⁵Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁶Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to…
Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Runsheng Wang¹, Abhijit Dasgupta² and Michael Ward³, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²NIAMS, Bethesda, ³National Institutes of Health, Bethesda, MD
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].